Bart Staels, PhD., is director of the Inserm Unit UMR1011 with laboratories at the Lille Pasteur Institute and Medical Faculty campus.

After his doctorate at the Univ.Leuven, Belgium, he completed his training at the UCSF, San Francisco and RPR, Paris. He is Senior Member of the Institut Universitaire de France, co-founder and board member of the European Genomic Institute for Diabetes (EGID, Lille), member of the French National Academy of Pharmacy and the Belgian Royal Academy of Medicine, and past-president of the French Atherosclerosis Society.

Awards: the EAS Young Investigator Award, the CNRS Bronze Medal, the Lifetime Achievement Award of the British Atherosclerosis Society, the “Barré” prize from the Faculté de Pharmacie of Montreal (2007), the “JP Binet” prize from the Fondation pour la Recherche Médicale (2011), the “Distinguished Leader in Insulin Resistance” award (2012), the ICBL Laurens van Deenen award (2017) and the European Atherosclerosis Society 2024 “Anitschkow Prize”.

B.Staels’ research covers the fields of obesity, diabetes, hepatic and cardiovascular diseases focussing on molecular pharmacology of these cardio-metabolic diseases. He particularly studies the role of nuclear receptors in the control of inflammation and lipid and glucose homeostasis as well as the transcriptional mechanisms involved.

B.Staels has published >900 articles, abstracts and book chapters (Google h-index: 186; >136000 citations).  He received the ISI citations award and is a 2018, 2022 and 2023 Web-of-Science Highly Cited Researcher